Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure (CARNEBI)

This study has been completed.
Sponsor:
Information provided by:
Centro Cardiologico Monzino
ClinicalTrials.gov Identifier:
NCT00517725
First received: August 16, 2007
Last updated: September 15, 2010
Last verified: September 2010
  Purpose

The investigators test the hypothesis that different beta-blockers had a different influence on chemoreceptor response and lung diffusion capacity.

Both could influence exercise capacity in normoxic as well as hypoxic conditions.


Condition Intervention Phase
Chronic Heart Failure
Drug: carvedilol
Drug: bisoprolol
Drug: Nebivolol
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function

Resource links provided by NLM:


Further study details as provided by Centro Cardiologico Monzino:

Primary Outcome Measures:
  • exercise capacity [ Time Frame: two months ]

Secondary Outcome Measures:
  • lung diffusion [ Time Frame: two months ]

Enrollment: 60
Study Start Date: July 2007
Study Completion Date: May 2010
Arms Assigned Interventions
Active Comparator: Carvedilol Drug: carvedilol
Active Comparator: Bisoprolol Drug: bisoprolol
Active Comparator: Nebivolol Drug: Nebivolol

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chronic heart failure patients in stable clinical condition

Exclusion Criteria:

  • No comorbidity
  • NYHA class IV
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00517725

Locations
Italy
Centro Cardiologico Monzino, University of Milan
Milan, Italy, 20138
Sponsors and Collaborators
Centro Cardiologico Monzino
Investigators
Principal Investigator: Piergiuseppe Agostoni, MD, PhD Centro Cardiologico Monzino
Study Chair: Giancarlo Marenzi, MD Centro Cardiologico Monzino
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Piergiuseppe Agostoni, Centro Cardiologico Monzino - Univeristy of Milan
ClinicalTrials.gov Identifier: NCT00517725     History of Changes
Other Study ID Numbers: R76-CCM S78/407
Study First Received: August 16, 2007
Last Updated: September 15, 2010
Health Authority: Italy: Ministry of Health

Keywords provided by Centro Cardiologico Monzino:
exercise
lung diffusion
hypoxia
chemoreceptor
beta-blockers
heart failure

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Carvedilol
Nebivolol
Bisoprolol
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Sympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists

ClinicalTrials.gov processed this record on August 28, 2014